# Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

> **NCT00829088** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** AZD2066

## Key facts

- **NCT ID:** NCT00829088
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** —
- **Final completion:** 2009-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2009-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829088, "Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00829088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*